Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Byakika Tusiime, Jayne ^a   Chinn, Leslie W ^b   Oyugi, Jessica H ^c   Obua, Celestino ^c   Bangsberg, David R ^d   Kroetz, Deanna L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE; TRIOMUNE 40; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEW DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; UGANDA; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACOKINETICS; SYNTHESIS;

ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; DRUGS, GENERIC; DRUGS, INVESTIGATIONAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; PATIENT COMPLIANCE; STAVUDINE; THERAPEUTIC EQUIVALENCY; UGANDA;

EID: 58049204452     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003981     Document Type: Article

References (15)

1. Narang VS, Lulla A, Malhotra G, Purandare S (2005) A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects. J Clin Pharmacol 45: 265-274.
2. Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, et al. (2007) Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. AIDS 21: 59-64.
3. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, et al. (2004) Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 36: 1100-1102.
4. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21: 965-971.
5. Mistri HN, Jangid AG, Pudage A, Gomes N, Sanyal M, et al. (2007) High throughput LC-MS/MS method for simultaneous quantification of lamivudine, stavudine and nevirapine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 853: 320-332.
6. Zhang P (2003) A simple formula for sample size calculation in equivalence studies. J Biopharm Stat 13: 529-538.
7. von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, et al. (2006) A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 62: 552-559.
8. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, et al. (2007) Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 8: 86-91.
9. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, et al. (2007) CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. Aids 21: 2191-2199.
10. Yuen GJ, Lou Y, Thompson NF, Otto VR, Allsup TL, et al. (2001) Abacavir/ lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol 41: 277-288.
11. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, et al. (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11: 399-415.
12. Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, et al. (2008) Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 61: 914-918.
13. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV (2006) Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 42: 441-449.
14. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, et al. (1995) High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171: 537-545.
15. World Health Organization Guidelines Development Group (2007) Important: Addendum to 2006 WHO Guidelines on Antiretroviral Therapy for HIV Infection in Adults and Adolescents. http://www.who.int/hiv/art/ ARTadultsaddendum.pdf.